Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A mouse model of Free Sialic Acid Storage Disorder: Hypomyelinating leukodystrophy and Purkinje cell degeneration

ABSTRACT: Free sialic acid storage disorder (FSASD) is a rare, neurodegenerative lysosomal storage disease caused by biallelic variants in SLC17A5, which encodes the lysosomal sialic acid exporter sialin. Although clinical severity varies, all affected individuals exhibit progressive neurological decline and characteristic lysosomal and urinary accumulation of free sialic acid, and no FDA-approved therapies currently exist, with the molecular basis of central nervous system dysfunction remaining poorly defined. To model the most prevalent disease-associated allele, a Slc17a5R39C mouse carrying the pathogenic p.Arg39Cys variant was generated using CRISPR/Cpf1. Homozygous Slc17a5R39C/R39C mice recapitulate key features of FSASD, including biochemical accumulation of free sialic acid, progressive ataxia, tremors, seizures, and reduced lifespan. Neuropathological analyses demonstrate widespread central nervous system hypomyelination with relative preservation of peripheral myelination, while transcriptomic profiling reveals broad suppression of myelin-associated genes alongside a cerebellum-specific inflammatory signature. These changes are accompanied by marked astrogliosis, progressive Purkinje cell degeneration, and increased neurofilament proteins, including serum NfL. Collectively, the Slc17a5R39C/R39C model provides critical insight into disease pathogenesis, highlights region-specific neurodegenerative vulnerability, and establishes a robust preclinical platform for mechanistic and therapeutic studies.

ORGANISM(S): Mus musculus

PROVIDER: GSE328153 | GEO | 2026/04/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

A mouse model of Free Sialic Acid Storage Disorder: Hypomyelinating leukodystrophy and Purkinje cell degeneration

Project description:A mouse model of Free Sialic Acid Storage Disorder: Hypomyelinating leukodystrophy and Purkinje cell degeneration

| PRJNA1454005 | ENA

RNA-Seq profiling of brain in Mucopolysaccharidosis type II mouse model

Project description:Lysosomal Storage Disorders (LSDs) are a group of about 50 metabolic disorders, sharing the inability to degrade specific endolysosomal substrates. This results in failure of cellular functions in many organ systems including brain in most patients, which show a progressive neurodegeneration. In this study we performed an RNA-Seq analysis of two brain areas (cerebral cortex and midbrain/diencephalon/hippocampus) of the mouse model for Mucopolysaccharidosis type II, a neurodegenerative LSD.

2017-05-19 | GSE95224 | GEO

Reactivation of mTOR signaling slows neurodegeneration in a lysosomal storage disease

Project description:Sandhoff disease, a lysosomal storage disorder, is caused by pathogenic variants in the HEXB gene, resulting in the loss of β-hexosaminidase activity and accumulation of GM2 ganglioside and GA2 glycolipid. This accumulation occurs primarily in neurons, and leads to progressive neurodegeneration through a largely unknown process. Lysosomal storage diseases often exhibit dysfunctional mTOR signaling, a pathway crucial for proper neuronal development and function. In this study, Sandhoff disease model mice exhibited reduced mTOR signaling in the brain. To test if restoring mTOR signaling could improve the disease phenotype, we genetically reduced expression of the mTOR inhibitor Tsc2 in these mice. Sandhoff disease mice with reactivated mTOR signaling displayed increased survival rates and motor function, especially in females, increased dendritic-spine density, and reduced neurodegeneration. Tsc2 reduction also partially rescued aberrant synaptic function–related gene expression. These findings imply that enhancing mTOR signaling could be a potential therapeutic strategy for lysosomal-based neurodegenerative diseases

2025-02-10 | GSE275408 | GEO

Gene expression profile of patients affected by Metachromatic Leukodystrophy (MLD)

Project description:The genome-wide analysis of T lympocytes from 24 MLD patients and a corresponding number of matched controls reveals a list of differentially expressed genes that can be used to build classifiers that correctly classify not only patients and controls with high sensitivity and specificity, but also MLD patients into early- and late-onset clinical classes. Among the most differentially expressed genes, the class of metallothioneins shows a consistent and significant over-expression, confirmed also in affected tissues of patients and mouse models of MLD and other Lysosomal Storage Disorders, indicating metallothioneins a novel dynamic biomarker of disease progression and treatment response in this class of diseases. Moreover, gene onthology analysis performed on the microarray data suggest an involvement of stress response- and autophagy-related pathways as pathological mechanisms in MLD. Total RNA extracted from T-lymphocytes of 24 MLD patients and 24 age-and sex-matched controls

2013-11-21 | E-GEOD-23350 | biostudies-arrayexpress

Transcriptomic profile of skeletal muscle in wild-type, GAA knock-out, and AAV treated GAA knock-out mice to understand Pompe disease mechanisms and assess therapeutic efficacy

Project description:Pompe disease (glycogen storage disease type II, or acid maltase deficiency) is an autosomal-recessive disorder of metabolism caused by mutations in the lysosomal hydrolase, acid alpha-glucosidase gene (GAA), resulting in progressive muscle atrophy. Gene therapy is a promising approach to treat genetic diseases, and liver-restricted expression of secretable GAA can produce immune tolerance and improve muscle GAA activity. To further understand the molecular mechanisms underlying Pompe disease and impact of gene therapy, we applied RNA sequencing.

2020-10-06 | GSE159063 | GEO

Massive accumulation of sphingomyelin affects the lysosomal and mitochondria compartments and promotes apoptosis in type A Niemann- Pick disease

Project description:Niemann-Pick type A disease (NPA) is a rare lysosomal storage disorder caused by mutations in the gene coding for the lysosomal enzyme acid sphingomyelinase (ASM). ASM deficiency leads to the consequent accumulation of its uncatabolized substrate, the sphingolipid sphingomyelin (SM), causing severe progressive brain disease. To study the effect of the aberrant lysosomal accumulation of SM on cell homeostasis we loaded skin fibroblasts derived from a NPA patient with exogenous SM to mimic the levels of accumulation characteristic of the pathological neurons. In SM-loaded NPA fibroblasts we found the blockage of the autophagy flux and the impairment of the mitochondrial compartment paralleled by the altered transcription of several genes, mainly belonging to the electron transport chain machinery and to the cholesterol biosynthesis pathway. In addition, SM loading induces the nuclear translocation of the transcription factor EB that promotes the lysosomal biogenesis and exocytosis. Interestingly, we obtained similar biochemical findings in the brain of the NPA mouse model lacking ASM (ASMKO mouse) at the neurodegenerative stage. Our work provides a new in vitro model to study NPA etiopathology and suggests the existence of a pathogenic lysosome-plasma membrane axis that with an impairment in the mitochondrial activity is responsible for the cell death.

2022-07-27 | GSE199194 | GEO

Skeletal muscle gene expression in the wild type and the GAA knock-out mice, a model of Pompe disease

Project description:Pompe disease is a Lysosomal glycogen storage disorder due to the deficiency of acid alpha glucosidase. The enzyme degrades glycogen to glucose and its deficiency results in progressive enlargement of glycogen-filled lysosomes in multiple tissues with skeletal and cardiac muscle most severely affected clinically. Clinical spectrum ranges from most severe infantile cardiomegally and skeletal muscle myopathy to milder late onset forms with only skeletal muscle pathology. The currently available enzyme replacement therapy has only limited effect in skeletal muscle. Here we use RNA sequencing of therapy-resistant skeletal muscle (white part of gastrocnemius muscle) to identify the differencies between the diseased and healthy muscle. Total RNA was obtained from gastrocnemius muscle (white part) of acid alpha glucosidase knock-out and wild-type mice.

2017-05-13 | E-GEOD-57980 | biostudies-arrayexpress

Gene expression profile of patients affected by Metachromatic Leukodystrophy (MLD)

2013-11-21 | GSE23350 | GEO

Plasma Membrane Remodelling in GM2 Gangliosidoses Drives Synaptic Dysfunction

Project description:Glycosphingolipids (GSL) are important bioactive membrane components. GSLs containing sialic acids, known as gangliosides, are highly abundant in the brain and diseases of ganglioside metabolism cause severe early-onset neurodegeneration. The ganglioside GM2 is processed by β-hexosaminidaseA and when non-functional GM2 accumulates causing Tay-Sachs and Sandhoff diseases. We have developed i3Neuron-based disease models demonstrating storage of GM2 and severe endolysosomal dysfunction. Additionally, the plasma membrane (PM) is significantly altered in its lipid and protein composition. These changes are driven in part by lysosomal exocytosis causing inappropriate accumulation of lysosomal proteins on the cell surface. There are also significant changes in synaptic protein abundances with direct functional impact on neuronal activity. Lysosomal proteins are also enriched at the PM in GM1 gangliosidosis supporting that lysosomal exocytosis is a conserved mechanism of PM proteome change in these diseases. This work provides mechanistic insights into neuronal dysfunction in gangliosidoses highlighting that these are severe PM disorders with implications for other lysosomal and neurodegenerative diseases.

2025-06-24 | PXD064632 | Pride

Lysosome Lipid Signaling from the Periphery to Neurons Regulates Longevity

Project description:<p>Lysosomes are key cellular organelles that metabolize extra- and intra-cellular substrates. Alterations in lysosomal metabolism are implicated in aging-associated metabolic and neurodegenerative diseases. However, how lysosomal metabolism actively coordinates the metabolic and nervous systems to regulate aging remains unclear. Here, we report a fat-to-neuron lipid signaling pathway induced by lysosomal metabolism and its longevity promoting role in <em>Caenorhabditis elegans</em>. We discovered that induced lysosomal lipolysis in peripheral fat storage tissue up-regulates the neuropeptide signaling pathway in the nervous system to promote longevity. This cell-non-autonomous regulation is mediated by a 47 specific polyunsaturated fatty acid, dihomo-gamma-linolenic acid (DGLA) and LBP-3 lipid chaperone protein transporting from the fat storage tissue to neurons. LBP-3 binds to DGLA, and acts through NHR-49 nuclear receptor and NLP-11 neuropeptide in neurons to extend lifespan. These results reveal lysosomes as a signaling hub to coordinate metabolism and aging, and lysosomal signaling mediated inter-tissue communication in promoting longevity.</p>

2022-05-06 | MTBLS4654 | MetaboLights

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data